"Pregnenediones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unsaturated pregnane derivatives containing two keto groups on side chains or ring structures.
| Descriptor ID |
D011282
|
| MeSH Number(s) |
D04.210.500.745.745.654
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pregnenediones".
Below are MeSH descriptors whose meaning is more specific than "Pregnenediones".
This graph shows the total number of publications written about "Pregnenediones" by people in this website by year, and whether "Pregnenediones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pregnenediones" by people in Profiles.
-
Bylo M, Farewell R, Coppenrath VA, Yogaratnam D. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy. Ann Pharmacother. 2020 08; 54(8):788-794.
-
Chrzanowski SM, Poudyal R. Deflazacort-New Costs of an Old Medicine. JAMA Neurol. 2018 Feb 01; 75(2):143-144.
-
Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter MM, Sawnani H, Jefferies JL. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment. J Pediatr. 2017 03; 182:296-303.e1.
-
Villa CR, Kaddourah A, Mathew J, Ryan TD, Wong BL, Goldstein SL, Jefferies JL. Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C. Neuromuscul Disord. 2016 10; 26(10):637-642.
-
Tandon A, Villa CR, Hor KN, Jefferies JL, Gao Z, Towbin JA, Wong BL, Mazur W, Fleck RJ, Sticka JJ, Benson DW, Taylor MD. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. J Am Heart Assoc. 2015 Mar 26; 4(4).
-
Golekoh MC, Hu S, Norman AM, Horn PS, Brady RC, Wong BL. Comparison of the immunogenicity of intramuscular versus subcutaneous administration of trivalent inactivated influenza vaccine in individuals with neuromuscular diseases. J Child Neurol. 2013 May; 28(5):596-601.
-
Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H, Hor KN, Cripe LH, Wong BL. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord. 2012 Dec; 22(12):1046-56.
-
Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008 May; 18(5):365-70.
-
Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol. 2005 Nov-Dec; 26(6):768-71.
-
Wong BL, Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol. 2002 Mar; 17(3):183-90.